Financial Reports
Our financial reports are only available in Swedish.
AcuCort publishes the Interim Report for the third quarter 2022 (in Swedish)
Calendar
-
14 April
-
28 April
Subscribe to AcuCort's newsletter
Message from the CEO
“AcuCort is entering a new and exciting phase, focusing on the commercialisation of our innovative and patient-friendly oral film Zeqmelit®, for acute and severe allergic reactions, among others.”
Jonas Jönmark, CEO, AcuCort AB
February 24, 2023
We make good drugs better
AcuCort develops innovative treatments based on existing and well-documented substances in treatment areas where there is a high unmet medical need and commercial interest in new drugs that add benefits such as simplicity of administration.
Latest videos from AcuCort
Acucort – Stora Aktiedagen Stockholm 15 mars 2023
AcuCort AB
March 16, 2023 09:45
AcuCort – Bokslutskommuniké 2022
AcuCort AB
February 24, 2023 10:48